IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

Feb 26th 2024- Prof. Marion Subklewe- Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Feb 5th 2024- Prof. Ali Bazarbachi- Sorafenib Plus Intensive Chemotherapy in Newly Diagnosed FLT3-ITD AML: A Randomized, Placebo-Controlled Study by the ALLG

Feb 23rd 2024- Guido Ghilardi & Marco Ruella- T-cell Lymphoma and Secondary Primary Malignancy Risk After Commercial CAR T-cell Therapy

Feb 14th 2024- Dr. Joshua Fein- Simple Score of Albumin and CRP Predicts High Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy

Feb 2nd 2024- Dr. Paula Rodriguez-Otero- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization approval for idecabtagene vicleucel (Abecma; ide-cel) for use in adult patients with relapsed and refractory multiple myeloma who previously received at least 2 therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody

Jan 23rd 2024- Prof. Daniel Wolff- Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with CGVHD Disease (AGAVE-201)

Jan 8th 2024- David Valcarcel & Adrian Mosquera- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Dec 19th 2023- Prof. Florent Malard- Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as a Predictor of Mortality in Children

Dec 12th 2023- Prof. Arnold Ganser – How I Treat Refractory and Relapsed Acute Myeloid Leukemia

Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study